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Abstract
Background: Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic
breast cancer patients whose tumors overexpress Her2 (erbB2/neu). Up to 70% of Her2-positive breast cancers demonstrate
a response to Herceptin-based therapies, but resistance almost inevitably arises within a year of the initial response. To help
understand the mechanism of Herceptin resistance, we isolated clonal variants of Her2-positive BT474 human breast cancer
cells (BT/Her
R) that are highly resistant to Herceptin. These cell lines exhibit sustained PI3K/Akt signaling as an essential
component of Herceptin-resistant proliferation. Several genes in the protein kinase A (PKA) signaling network have altered
expression in BT/Her
R cells, including PPP1R1B, which encodes a 32 kDa protein known as Darpp-32 and its amino-terminal
truncated variant, t-Darpp. The purpose of the current work was to determine the role of Darpp-32 and t-Darpp in Herceptin
resistance.
Methodology and Results: We determined expression of Darpp-32 and t-Darpp in BT/Her
R cells selected for resistance to
Herceptin. Subsequently, cDNAs encoding the two isoforms of Darpp-32 were transfected, separately and together, into
Her2-positive SK-Br-3 breast cancer cells. Transfected cells were tested for resistance to Herceptin and Herceptin-mediated
dephosphorylation of Akt. DNA binding activity by the cAMP response element binding protein (CREB) was also measured.
We found that BT/Her
R cells overexpressed t-Darpp but not Darpp-32. Moreover, t-Darpp overexpression in SK-Br-3 cells was
sufficient for conferring resistance to Herceptin and Herceptin-mediated dephosphorylation of Akt. Darpp-32 co-expression
reversed t-Darpp’s effects on Herceptin resistance and Akt phosphorylation. t-Darpp overexpression led to increased CREB
binding activity, which was also reversible by Darpp-32.
Conclusions: t-Darpp and Darpp-32 appear to have antagonistic effects on Herceptin resistance. We present a unified
model by which these effects might be mediated via the PKA regulatory network.
Citation: Gu L, Waliany S, Kane SE (2009) Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin
Resistance. PLoS ONE 4(7): e6220. doi:10.1371/journal.pone.0006220
Editor: Mikhail V. Blagosklonny, Roswell Park Cancer Institute, United States of America
Received March 27, 2009; Accepted June 11, 2009; Published July 13, 2009
Copyright:  2009 Gu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported entirely by institutional funds, with no extramural funding. Institutional officials had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: skane@coh.org
Introduction
Her2, a member of the ErbB family of receptor tyrosine kinases,
is overexpressed in about 25% of human breast cancers [1].
Herceptin (trastuzumab) is a humanized monoclonal antibody
targeted to Her2 and approved for use against Her2-positive
metastatic breast cancer [2]. Despite a fairly robust response rate
to Herceptin-based therapies in these patients, resistance fre-
quently arises within one year of an initial response [3–7]. The
determinants of response or resistance to anti-cancer drugs are
often complex. In the case of Herceptin, which works primarily by
shutting down the PI3K/Akt signal transduction pathway, the key
determinant of response appears to be the ability to modulate Akt
phosphorylation. Failure to modulate phospho-Akt results in
resistance [8–10].
Cells have several mechanisms by which to sustain Akt signaling
in the face of Herceptin [9,11], including mutation of PIK3A, the
gene that codes for the p110a catalytic subunit of PI3K [12,13];
mutation or deletion of PTEN, whose product is a dual lipid/
protein phosphatase responsible for down-modulating phosphati-
dyl-inositol 3,4,5 triphosphate that is the product of PI3K [13–15];
up-regulation or activation of receptor tyrosine kinases such as
EGFR, Her3, IGFR1 or MET to compensate for Her2 inhibition
[16–20]; down-regulation of phosphatases that are responsible for
dephosphorylating Akt as a negative feedback mechanism [21,22];
and up-regulation of phosphatase inhibitors that modulate the
effect of those phosphatases and thus dampen the negative
feedback [23]. There are also ways of bypassing phospho-Akt
altogether, either by promoting signal transduction at a point
downstream of Akt or by activating a parallel pathway(s) that can
compensate for loss of PI3K/Akt signaling [24–26].
Using BT/Her
R1.0 cell lines selected in vitro for their resistance
to 1 mM Herceptin [8], we have identified the protein kinase A
(PKA) pathway as a possible central regulator of PI3K/Akt
signaling and possible compensatory pathway for survival in the
presence of Herceptin. In a separate report, we demonstrate that
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RIIa regulatory subunit of PKA with siRNA was sufficient for
conferring partial resistance to Herceptin-mediated growth arrest
and Akt dephosphorylation (L. Gu and S.E. Kane, manuscript
submitted). Additional PKA-related gene expression changes
observed in BT/Her
R1.0 clones include down-regulation of the
PKIc gene, whose product acts as an endogenous inhibitor of PKA
[27]; down-regulation of the gene that codes for PTG (protein
targeting to glycogen), a scaffold protein [28] that promotes the
activity of PP-1, a downstream target for negative regulation by
PKA and itself a negative regulator of Akt; and up-regulation of
the PPP1R1B gene, which codes for Darpp-32, a substrate for and
feedback inhibitor of PKA and also an inhibitor of PP-1 [29]. The
PPP1R1B locus also codes for t-Darpp, a transcriptional variant
and amino-truncated isoform of Darpp-32 whose function within
the PKA pathway is not known, but which is overexpressed in
many adenocarcinomas and has been associated with drug
resistance in cell lines [30–33].
We now demonstrate that it was t-Darpp, and not Darpp-32,
that was overexpressed in BT/Her
R cells selected for Herceptin
resistance and that transfection and overexpression of exogenous t-
Darpp in Her2-positive SK-Br-3 cells was sufficient for conferring
resistance to Herceptin and Herceptin-mediated dephosphoryla-
tion of Akt. Darpp-32 co-expression reversed t-Darpp’s effects on
Herceptin resistance and Akt phosphorylation. Overexpression of
t-Darpp also led to increased CREB binding activity, which was
also reversible by Darpp-32. We present a model by which the
PKA pathway and its regulatory components might impact
cellular response to Herceptin.
Materials and Methods
Cell culture
The human breast cancer cell lines BT474 and SK-Br-3 were
obtained from the American Type Culture Collection (Rockville,
MD). BT474 cells were maintained in DMEM with 10% FBS and
1% penicillin/streptomycin in 5% CO2. BT/Her
R clones,
previously derived from BT474 cells after a six-month selection
in the continuous presence of Herceptin [8], were maintained in
the same culture conditions as the BT474 cells. They were
regularly tested in Herceptin-containing medium to verify their
drug resistance. SK-Br-3 cell clones were maintained in McCoy’s
Medium 5A with 10% FBS, 1% penicillin/streptomycin, and
1%L-glutamine in 5% CO2.
Stable transfections
Darpp-32 and t-Darpp cDNAs were a kind gift from Wael El-
Rifai. Darpp-32 was in the pcDNA3.1/Zeo vector. We subcloned
the t-Darpp cDNA into the pcDNA3.0/Neo vector to remove a
FLAG-tag present at the N-terminus of the received cDNA and
restore its native sequence. Plasmid DNAs were transfected into
SK-Br-3 cells or clones derived from SK-Br-3 cells by Lipofecta-
mine 2000 according to manufacturer’s instruction. SK-Br-3 cells
transfected with a pcDNA3.0/Neo vector backbone were selected
and maintained in the presence of 500 mg/ml G418. SK-Br-3 cell
clones transfected with a pcDNA3.1/Zeocin vector backbone were
selected and maintained in the presence of 200 mg/ml Zeocin.
RNA preparation and real time RT-PCR
Total RNA was extracted and purified using the RNeasy kit
purchased from Qiagen (Valencia, CA) and the integrity of the
RNA was verified using the Agilent Technologies Bioanalyzer 2100
(Santa Clara, CA). cDNAs were synthesized by random priming,
using purified total RNA as template. The t-Darpp and Darpp-32
mRNA levels were quantified by a SYBR
H Green assay, using a
reaction mixture purchased from Applied Biosystems (Foster City,
CA). Primers 59-TCTGCCTCTCCCGTCCTTCTand 59-AGA-
GACACACGCGGAGAGGAwere used for quantifying Darpp-32
mRNA and primers59-TGAGGCTCAGGGACCCAAAG and 59-
CTGCAGCCTTACAGAGACTGG were used for quantifying t-
Darpp mRNA. The PCR and real time quantification were carried
out in an auto-lid dual 384-well GeneAmpH PCR System (Model
9700, Applied Biosystems). Quadruplicate measurements were
made on a single isolation of RNA from each cell line analyzed.
Statistical significances were determined by two-tailed t-test.
Raw microarray data referenced as part of a separate report are
described in accordance with MIAME guidelines and are
deposited in the Gene Expression Omnibus database, Accession
No. GSE15043).
Sulforhodamine B (SRB) assay
Cells were seeded into each well of 96-well tissue culture plates
at a density of 4610
3/well and allowed to attach overnight. On
day 0, medium with or without Herceptin was added. After
growing in the presence or absence of Herceptin for 7 days, cells
were fixed with 10% trichloroacetic acid and stained with 0.4%
SRB (w/v) (Sigma, Saint Louis, MO) according to manufacturer’s
instructions. 10 nM Tris Base solution was used to solubilize the
bound stain and absorbances at 565 nm were measured.
Antibodies and Western analysis
A rabbit monoclonal antibody recognizing the N-terminal
sequence that is unique to the Darpp-32 protein (#2302) and a
rabbit monoclonal antibody recognizing only Akt/PKB that is
phosphorylated on Ser473 (#4058) were purchased from Cell
Signal Technologies (Danvers, MA). A rabbit polyclonal antibody
recognizing both Darpp-32 and t-Darpp (H-62) and a rabbit
polyclonal antibody recognizing total Akt/PKB (sc-8312) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Cell
samples were dissolved and sonicated in 2x Laemmli sample
buffer. After boiling for five minutes, equal amounts of total
protein, as determined by the RC DC Protein Assay kit purchased
from Bio-Rad (Hercules, CA), were loaded onto a 10% SDS-
polyacrylamide gel and separated proteins were transferred onto a
nitrocellulose membrane. The membrane was blocked with 5%
non-fat dry milk and incubated with primary antibody in the
blocking buffer. After incubation with a peroxidase-conjugated
anti-mouse IgG secondary antibody, the protein of interest was
detected using an ECL kit purchased from GE HealthCare
(Piscataway, NJ). For repeated antibody probing, the membrane
was stripped with a Western blot stripping buffer purchased from
Pierce (Rockford, IL).
Electrophoretic mobility shift assay
Nuclear extracts were prepared using CelLytic
TM NuCLE-
AR
TM Extraction Kit (Sigma, Saint Louis, MO). Electrophoretic
mobility shift assay (EMSA) was done using a gel shift assay kit
purchased from Promega (Madison, WI) according to manufac-
turer’s instructions. Briefly, double-stranded oligonucleotide con-
taining a consensus CREB (cyclic AMP response element-binding
protein) response element (CRE) was labeled with c-
32P ATP by
end-labeling. DNA-protein binding reactions were performed by
incubating 5 mg of nuclear protein with excess
32P-labeled CRE
oligonucleotide in the buffer supplied with the assay kit. For
competition binding, 1 pmol of an unlabeled CRE oligonucleotide
or an unlabeled non-specific oligonucleotide was added. After
incubation at room temperature for 20 min, binding reactions
were resolved on a 4% native polyacrylamide gel. The gel was
t-Darpp and Resistance
PLoS ONE | www.plosone.org 2 July 2009 | Volume 4 | Issue 7 | e6220then dried onto Whatman paper and radioactivity was visualized
by autoradiography. The autoradiography images were digitized
by a high-resolution scanner and the densities of individual bands
were measured by ImageQuant
MT 5.2 (GE Healthcare, Piscat-
away, NJ).
Results
Enhanced expression of t-Darpp in BT/Her
R cell clones
We previously reported on the isolation and initial character-
ization of BT/Her
R1.0 cell lines selected for their resistance to
Herceptin at 1.0 mM concentration [8]. A salient feature of BT/
Her
R1.0 cells is their sustained phospho-Akt levels and Akt activity
in the presence of Herceptin. As part of a separate study, gene
expression profiling revealed that the PPP1R1B gene was up-
regulated by 9- to 50-fold in two independent BT/Her
R1.0 clones
(raw microarray data are deposited in the Gene Expression
Omnibus database, Accession No. GSE15043).
PPP1R1B encodes two transcription variants, Darpp-32 and t-
Darpp [34], both of which hybridize to the same probe set on the
Affymetrix GeneChip Human Genome U133 plus v2.0 array used
for this analysis. To determine if one or both transcription variants
encoded by the PPP1R1B gene were up-regulated in BT/Her
R1.0
clones, we extracted RNAs from parent BT474 cells and two BT/
Her
R1.0 clones and measured Darpp-32 and t-Darpp mRNA
levels in these cells. BT/Her
R0.2 clones, which did not have up-
regulated PPP1R1B in the microarray analysis (data not shown),
were also analyzed in this experiment. Quantitative real-time RT-
PCR revealed an increase in the t-Darpp mRNA levels in BT/
Her
R cells relative to parent BT474 cells, including a slight
increase in the BT/Her
R0.2 clones (Fig. 1A). In contrast, no
significant up-regulation of Darpp-32 mRNA levels was observed
in BT/Her
R cells vs. BT474 cells. Consistent with the quantitative
RT-PCR data, Western analysis confirmed that t-Darpp protein
expression was up-regulated in all BT/Her
R clones analyzed,
whereas BT/Her
R clones and their parent BT474 cells expressed
similarly low levels of Darpp-32 protein (Fig. 1B). A longer
exposure of the gel revealed detectable expression of the full-length
Darpp-32 protein and perhaps a modest elevation of this protein
in BT/Her
R cells, relative to BT474 cells (Fig. 1B), but t-Darpp
was clearly the predominant variant overexpressed in BT/Her
R
cells. This might suggest an overall activation of the PPP1R1B
locus in these cells but preferential transcription from the
downstream start site controlling t-Darpp mRNA expression.
Since the protein data are not absolutely correlated with the
mRNA data in Fig. 1A, there might also be an element of
translational or post-translational control over Darpp-32/t-Darpp
expression that is currently not understood. Further analysis of the
PPP1R1B locus will be required to clarify the mechanisms
regulating expression at the mRNA and protein levels.
Overexpression of t-Darpp confers Herceptin resistance
The purpose of the current study was to determine the
phenotypic consequence of activating expression from the
PPP1R1B locus. Since t-Darpp was the predominant form of the
protein being expressed, we first asked if enhanced expression of t-
Darpp is sufficient for conferring Herceptin resistance. We
transfected a Her2-positive, Herceptin-sensitive human breast
cancer cell line, SK-Br-3, with a cloned human t-Darpp cDNA as
described in Materials and Methods. Independent clones stably
transfected with either the empty vector (SK.Neo) or the t-Darpp
vector (SK.tDp) were isolated. Western analysis confirmed that
parent SK-Br-3 cells and SK.Neo clones expressed no detectable
levels of t-Darpp or Darpp-32, whereas SK.tDp clones expressed
significant levels of t-Darpp protein (Fig. 2A). Herceptin inhibited
the growth of the parent SK-Br-3 cells and SK.Neo clones but had
no significant effect on the growth of SK.tDp clones (Fig. 2B).
As a further test of the role of t-Darpp in Herceptin resistance,
we measured phospho-Akt levels in SK.tDp and SK.Neo clones in
the presence and absence of Herceptin. Herceptin caused an
almost complete dephosphorylation of Akt in SK.Neo clones,
whereas SK.tDp clones were able to maintain a significant level of
intracellular phospho-Akt in the presence of Herceptin (Fig. 2C).
Interestingly, we observed a reduction in phospho-Akt levels in
some SK.tDp clones at 1 hour after the addition of Herceptin,
followed by quick restoration of phospho-Akt by 2–3 hours in the
sustained presence of Herceptin (Fig. 2C and data not shown),
although this result was not reproducible in all clones. Although
we do not know the reason for the transient loss of phospho-Akt in
some SK.tDp clones, it suggests that Her2’s immediate response to
Herceptin remains intact in at least some cell lines that overexpress
t-Darpp.
Darpp-32 reverses Herceptin resistance conferred by t-
Darpp
Although t-Darpp expression has been associated with malig-
nant transformation and drug resistance, its exact mechanism of
action is not known. The full-length Darpp-32, on the other hand,
has been extensively studied in neural systems [29] but its possible
function in malignancy is not known. We wanted to determine the
effect of expressing high levels of Darpp-32 in the presence and
absence of its truncated variant, t-Darpp. We transfected SK-Br-3
cells with the pcDNA3.1/Darpp-32 vector as described in
Materials and Methods and tried to select clones stably expressing
the full-length protein. Transfected clones grew poorly, however,
and none with confirmed Darpp-32 expression survived long-term
culturing. Out of a combined total of about 50 Zeocin-selected
clones isolated from several independent transfection experiments,
only 12 were able to grow as cultures and none of those expressed
detectable levels of Darpp-32 protein.
These results suggested that Darpp-32 overexpression might be
detrimental to cell proliferation and/or survival in SK-Br-3 cells. If
true, then Darpp-32 and t-Darpp would appear to have opposite
effects on cell growth. If Darpp-32 and t-Darpp do functionally
antagonize each other, we reasoned that enhanced expression of
Darpp-32 might reverse the Herceptin resistance phenotype
conferred by t-Darpp overexpression. To test this hypothesis, we
transfected Darpp-32 cDNA into the Herceptin-resistant
SK.tDp.A clone and selected for zeocin-resistant clones. Out of
11 surviving clones tested, six expressed full-length Darpp-32 in
addition to t-Darpp that was already expressed in these cells
(Fig. 3A and data not shown). Thus, the presence of t-Darpp
appeared to create a permissive environment for enhanced Darpp-
32 expression that otherwise could not be achieved. We next tested
these cells for their response to Herceptin. The SK.tDp/Dp32
clones that expressed both t-Darpp and Darpp-32 were sensitive to
Herceptin-induced growth arrest (Fig. 3B). Moreover, Herceptin
caused nearly a complete dephosphorylation of Akt in SK.tDp/
Dp32 clones, similar to that observed in the parent SK-Br-3 cells
(Fig. 3C) and SK.Neo clones (not shown).
t-Darpp and Darpp-32 have antagonistic effects on CRE
binding activities
Darpp-32 is a substrate for and negative regulator of PKA.
Although the relationship between t-Darpp and PKA has yet to be
elucidated, El-Rifai’s group recently reported that exogenous
expression of t-Darpp in AGS gastric carcinoma cells leads to
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increased CRE binding activity [32]. One explanation for this
observation may be that, opposite to Darpp-32, t-Darpp acts as an
activator of PKA or has a dominant-negative effect on Darpp-32’s
inhibitory activity. To determine the effect of t-Darpp and Darpp-
32 overexpression on PKA activity, we performed an electropho-
retic mobility shift assay on nuclear extracts derived from
SK.tDp.A cells and three independent SK.tDp/Dp32 clones,
using a consensus CRE sequence as probe. Parent SK-Br-3 cells
and a SK.Neo clone were used as controls. The nuclear extract
from clone SK.tDp.A that expressed t-Darpp alone contained
higher CRE binding activity than the controls (Fig. 4). Conversely,
nuclear extracts derived from three independent SK.tDp/Dp32
clones that expressed both t-Darpp and Darpp-32 had reduced
CRE binding activity relative to the SK.tDp.A clone from which
they were derived. Although we do not know if the observed
changes in CRE binding activity due to exogenous expression of t-
Darpp alone or co-expression of t-Darpp and Darpp-32 were
mediated directly through the PKA pathway, this result is certainly
compatible with an effect of these proteins on PKA signaling.
Discussion
We have previously reported on the isolation and initial
characterization of BT/Her
R1.0 cells that are highly resistant to
Herceptin [8]. Those cells were derived by culturing the Her2-
dependent, Herceptin-sensitive BT474 human breast cancer cells
in the presence of 1.0 mM Herceptin for 5–6 months. Gene
Figure 1. Expression of Darpp-32 and t-Darpp in BT/Her
R cells. (A) Expression of Darpp-32 (open bars) and t-Darpp (filled bars) mRNA in
BT474 cells and BT/Her
R clones was analyzed by a SYBR Green assay. Shown are the average expression levels (6S.D.) of Darpp-32 and t-Darpp
mRNAs in each indicated cell line relative to the corresponding mRNA levels in BT474 cells. Quadruplicate measurements were made on a single
isolation of RNA from each cell line analyzed. Statistically significant differences from BT cells were determined by two-tailed t-test. *, p,0.05; **,
p,0.01, ***, p,0.001. (B) Expression of Darpp-32 and t-Darpp proteins in BT474 and Her
R/BT clones was analyzed by Western hybridization. SK-Br-3
cells exogenously expressing both t-Darpp and Darpp-32 (tDp/Dp32) were used as control for the respective forms of the protein; this lane was
loaded with one-fifth as much lysate as the other lanes to account for their high exogenous t-Darpp/Darpp-32 expression. The top panel shows a
short-exposure image of the membrane stained with an antibody (Santa Cruz H-62) that recognizes both Darpp-32 and t-Darpp. The middle panel is a
long exposure of the same membrane and the bottom image shows the levels of actin as a loading control. Numbers below the actin image indicate
the ratio of Darpp-32 to t-Darpp signal for each lane in the middle panel, as determined by densitometric scanning. Clones shown in this figure and
additional BT/Her
R clones have been analyzed multiple times by Western analysis, always with very high t-Darpp expression and low or undetectable
expression of Darpp-32.
doi:10.1371/journal.pone.0006220.g001
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complement of gene expression changes in BT/Her
R clones.
That analysis revealed changes in a number of genes that intersect
with the PKA signaling pathway as either direct or indirect
regulators of PKA activity. These include down-regulation of the
gene for PKA-RIIa, a PKA regulatory subunit; down-regulation of
PKIc, an endogenous inhibitor of PKA [27]; upregulation of
PPP1R1B, which codes for Darpp-32 and its transcriptional
variant t-Darpp [29,34]; and down-regulation of PPP1R3C, whose
gene product has multiple functions including promotion of
protein phosphatase-1 (PP-1) activity and modulation of Darpp-32
function [28]. The net effect of these changes is 2- to 4-fold
activation of PKA signaling activity in BT/Her
R cells (manuscript
submitted).
In the current report, we demonstrate that it is the amino-
terminal truncated protein, t-Darpp, that was predominantly
overexpressed in BT/Her
R cells selected for Herceptin resistance
(Fig. 1) and that exogenous overexpression of t-Darpp was
sufficient for conferring Herceptin resistance on Her2-positive
SK-Br-3 cells (Fig. 2). These results are consistent with the recent
report from Belkhiri et al. using independently derived Herceptin-
resistant cell lines and transfected cells [31]. Hamel et al. also
demonstrate that t-Darpp overexpression can confer resistance
[35]. We go on to demonstrate that high expression of the full-
length protein, Darpp-32, was able to reverse t-Darpp’s effects on
Herceptin-resistant cell growth and phospho-Akt levels (Fig. 3). In
fact, overexpression of Darpp-32 alone appeared to be deleterious
to cell survival, since we were never able to obtain long-term
cultures of SK-Br-3 cells that overexpress Darpp-32. These data
suggest that Darpp-32 and t-Darpp have antagonistic effects on
cell growth and/or survival.
In addition to conferring Herceptin resistance, t-Darpp is also
reported to confer resistance to drug-induced apoptosis, appar-
ently via a mechanism that involves CREB activation [32]. We
also show a relationship between t-Darpp overexpression and
CREB activation and this was reversed by co-expression of Darpp-
32 (Fig. 4). Although not definitive, the most likely means by which
CREB is influenced by t-Darpp/Darpp-32 is via the PKA
signaling pathway. This would be consistent with the overall
implication of PKA regulatory proteins in Herceptin resistance
discussed earlier and the known function of Darpp-32 as a PKA
inhibitor [29], but the mechanism by which t-Darpp might
influence this pathway is not known. Because the full-length
Darpp-32 is both a substrate for phosphorylation by PKA (at Thr-
34) and a feedback negative regulator of PKA, it is interesting to
speculate that t-Darpp might function by antagonizing Darpp-32’s
Figure 2. Overexpression of t-Darpp confers Herceptin resistance. (A) SK-Br-3 cells transfected with an empty pcDNA3.0/Neo vector (Neo1
and Neo2) or with a pcDNA3.0/t-Darpp vector (tDp.A, J, L, and O) were analyzed by Western hybridization using the anti-Darpp-32 antibody (H-62) to
determine expression of t-Darpp in the transfected cells. (B) Growth of the indicated cell lines was analyzed in the presence or absence of 0.1 mMo r
0.3 mM Herceptin, as indicated, for 7 days using a Sulforhodamine B (SRB) assay. Shown are the absorbances of the cells (average of quadruplicate
platings, +S.D.) incubated in the presence of Herceptin, normalized to the same cells grown in the absence of Herceptin. (C) Western hybridization
was used to measure total Akt and phospho-Akt levels in the indicated clones at various times after the addition of 0.2 mM Herceptin. This experiment
was performed twice on the clones shown in this figure and once on an additional clone not shown. Similar results were obtained in both
experiments, although clone tDp.A also showed suppression of phospho-Akt levels at the 1 hr time point in the other experiment, with full recovery
by 2 hrs (see text).
doi:10.1371/journal.pone.0006220.g002
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pcDNA3.1/Zeo vector (NZ1 and NZ2) or with the pcDNA3.1/Darpp-32 vector (tDp/Dp32.A, D, F, and K). Expression of t-Darpp and Darpp-32 in these
cell lines and parent SK-Br-3 cells was analyzed by Western hybridization using the H-62 anti-Darpp-32 antibody. (B) Growth of SK-Br-3, tDp.A, and
tDp/Dp32.D, F, and K was analyzed in the presence and absence of Herceptin (0.1 mM or 0.3 mM) for 7 days. Shown are the absorbances (average of
triplicate wells, +S.D.) for cells incubated in the presence of Herceptin, normalized to the same cells grown in the absence of Herceptin. (C) Total and
phospho-Akt levels in SK-Br-3, tDp/Dp32.D, and tDp/Dp32.F clones at the indicated times (hrs) after the addition of Herceptin, analyzed by Western
hybridization. This experiment was performed three times, twice with 1.0 mM Herceptin, once with 0.2 mM Herceptin. We show the results with
0.2 mM Herceptin, representative of all three experiments showing loss of phospho-Akt signal by 4 hours.
doi:10.1371/journal.pone.0006220.g003
Figure 4. t-Darpp and Darpp-32 have antagonistic effects on CRE binding activity. Nuclear CRE binding activity in parent SK-Br-3 cells (SK)
and the indicated transfected clones was analyzed by EMSA, as described in Materials and Methods. Quantification of band density, relative to the SK
lane, is shown below each lane. The experiment was performed twice and the relative band densities for the other experiment were 1.9 for tDp.A and
1.1, 0.5 and 0.4 for the three tDp/Dp32 clones, respectively.
doi:10.1371/journal.pone.0006220.g004
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The downstream effects of PKA signaling include phosphorylation
and activation of full-length Darpp-32 as a PP-1 inhibitor [29].
Notably, the Thr-34 phosphorylation site and PP-1 binding
domain are missing from t-Darpp, suggesting that its overexpres-
sion should not have a direct effect on PP-1 activity.
There could be multiple downstream effects of PP-1 inhibition
and/or PKA activation, including the sustained phosphorylation
and constitutive activation of Akt that is observed in Herceptin
resistant cells. As noted earlier, Belkhiri et al. found that t-Darpp is
anti-apoptotic and promotes resistance to cytotoxic agents,
additional effects that could be mediated through PP-1 or more
directly through PKA [31,32]. One final observation from our
reported microarray data is the down-regulation of PPP1R3C in
BT/Her
R1.0 clones. The corresponding gene product, PTG, is a
scaffolding protein that can stimulate PP-1 activity and also has
been reported to interfere with Darpp-32’s inhibition of PP-1 [28].
Thus, down-regulation of PTG would be consistent with a
mechanism that results in overall inhibition of PP-1 and sustained
Akt phosphorylation.
Based on the findings in the current report, our previous
observations on the role of PKA and its regulatory proteins in
Herceptin resistance, and the work of Belkhiri et al., we propose a
working model in which down-regulation of PKA-RIIa, PKIc and
PTG and up-regulation of t-Darpp work in concert to enhance
PKA enzyme activity and inhibit PP-1, thereby allowing sustained
activation of the PI3K/Akt pathway in the presence of Herceptin,
and promoting cell growth and survival. This model is illustrated
in Fig. 5. Additional direct or indirect effects of t-Darpp
overexpression on Her2 or Akt or other downstream effects of
PKA dysregulation, as suggested by Belkhiri et al. [31], might also
contribute to the resistance phenotype. It is worth noting that this
same group has not reported the anti-resistance effects of Darpp-
32 overexpression that we demonstrate here. In fact, those authors
claim that Darpp-32 is able to confer resistance to chemotherapy-
induced apoptosis in a colon cancer cell line (RKO) and a gastric
cancer cell line (AGS) [33]. Interestingly, Darpp-32 (but not t-
Darpp) overexpression results in increased basal apoptosis rates in
AGS cells and the protection against drug-mediated apoptosis is
more pronounced with t-Darpp overexpression than with Darpp-
32 overexpression in those cells. This is especially true for
ceramide, a drug that activates protein phosphatases such as PP-1
and PP2A, thus indirectly inhibiting Akt signaling. Hamel et al.
also suggest that Darpp-32 is able to confer resistance to Herceptin
Figure 5. A working model of Herceptin resistance in BT/Her
R cells. Several intracellular changes, including down-regulation of PKA-RIIa,
PKIc and PTG (green arrows) and up-regulation of t-Darpp (red arrow) work coordinately to enhance PKA activity. PKA, in turn, either activates the
PI3K/Akt pathway (possibly through EGFR or the p85 regulatory subunit of PI3K) or promotes sustained phospho-Akt levels by activating the PP-1
inhibitory activity of Darpp-32. This activity is stimulated via a phosphorylation event at Thr-34, which is absent from t-Darpp. A second
phosphorylation event, at Thr-75, activates Darpp-32 as a PKA inhibitor. We speculate that t-Darpp may interfere with this PKA inhibition via a
dominant negative mechanism. Dashed lines indicate activities that are down-regulated in BT/Her
R cells relative to BT474 cells. Question marks
indicate hypothetical pathways that are activated in BT/Her
R cells. All other pathways represent well established activities associated with the
indicated proteins and enzymes. Abbreviations not already cited: PDK1/2, 3-phosphoinositide-dependent kinase-1/2; Pten, phosphatase and tensin
homologue deleted in chromosome 10; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate.
doi:10.1371/journal.pone.0006220.g005
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in cells analyzed for the Herceptin phenotype in that study. The
possible conflicts or overlaps between our current observations and
those of Belkhiri et al. and Hamel et al. still need to be resolved, but
they could be due to different cell lines used, different levels of
exogenous gene expression, or other factors affecting the
intracellular function of Darpp-32.
There could be a broader role for t-Darpp and/or Darpp-32 in
malignancy, beyond an involvement in drug resistance. A
protein(s) cross-reacting with Darpp-32 antibody and mRNA
corresponding to Darpp-32 and t-Darpp are detected in a variety
of adenocarcinomas, including breast cancers [30,33,34]. Using
antibodies that detect either Darpp-32 alone or both Darpp-32
and t-Darpp, we have found frequent high-level expression of one
or both proteins in both Her2-positive and Her2-negative breast
cancers (unpublished observations). Work in the current report
would suggest that it is t-Darpp, or perhaps the ratio between t-
Darpp and Darpp-32, that is critical for both malignant growth
and clinical outcome of these cancers, but further analysis will be
required to determine if this is the case. If it is, then t-Darpp (or,
more generally, the PKA pathway) could become a new target for
therapy and/or a biomarker for response to drug therapy.
Moreover, it will be interesting to study the mechanism by which
cells regulate expression from the upstream (Darpp-32) and
downstream (t-Darpp) transcriptional start sites in the PPP1R1B
gene, since shifting the balance towards the t-Darpp start site could
have profound effects on both malignancy and drug resistance.
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